Table 4.
Association of the DNA damage response deficiency (DDRD) assay with estrogen receptor (ER) status, HER2 status, and lymphocytic infiltration within validation datasets
| Adjuvant dataset | Total No. | DDRD- positive, % | P* |
|---|---|---|---|
| Adjuvant | |||
| ER-positive | 112 | 25.0 | <.001 |
| ER-negative | 77 | 52.0 | |
| HER2-positive | 46 | 41.3 | .26 |
| HER2-negative | 128 | 32.0 | |
| Triple negative | 44 | 54.6 | .001 |
| Non–triple negative | 135 | 28.2 | |
| Lymphocytic infiltrate positive | 35 | 74.3 | <.001 |
| Lymphocytic infiltrate negative | 155 | 27.7 | |
| Neoadjuvant | |||
| ER-positive | 70 | 24.3 | <.001 |
| ER-negative | 134 | 67.9 | |
* A two-sided χ2 test was used to assess the statistical significance of the univariate association between the DDRD assay and each clinical factor.